Adams sues Perrigo
This article was originally published in The Tan Sheet
Adams Respiratory Therapeutics filed suit Sept. 27 in U.S. District Court for the District of New Jersey against Perrigo, alleging infringement of Adams' '252 patent for the Mucinex line of extended-release guaifenesin products. The lawsuit responds to the private labeler's filing of a Paragraph IV certification for an ANDA for a 600 mg guaifenesin tablet, equivalent to single-ingredient Mucinex, and initiates a 30-month stay, preventing FDA from approving Perrigo's product unless a court rules against Adams or that period expires (1"The Tan Sheet" Aug. 27, 2007, p. 12)...
You may also be interested in...
Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.